Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Chief Scientific Officer | December 20, 2023 | December 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date December 20, 2023 · Filed December 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 834,931 |
Reported balance
After 2023-12-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-20 · Gift · Disposed 24,158 · Balance 834,931 F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 15,000 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectAs UTMA custodian for sons | 350 |
Reported balance
Holding disclosure · report date 2023-12-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 350 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation.
F2: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2023 Filed Dec 21, 2023 17:47 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 24,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000203 · wk-form4_1703198862.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 834,931 F1 · balance_after: The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 19:19 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 983 | $19.91 | $19,571.73 |
DisclosureSEC source: 0001725160-23-000180 · wk-form4_1696634351.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 859,089 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 19:19 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,085 | $19.43 | $98,783.75 |
DisclosureSEC source: 0001725160-23-000180 · wk-form4_1696634351.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 860,072 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2023 Filed May 31, 2023 21:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 80,000 | $30.02 | $2,401,248.00 |
DisclosureSEC source: 0001725160-23-000124 · wk-form4_1685581781.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Indirect · See Footnote Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.10. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 14, 2023 Filed Feb 14, 2023 19:07 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,500 | $19.98 | $129,873.25 |
DisclosureSEC source: 0001725160-23-000031 · wf-form4_167641965116508.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 865,157 F3 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.73 to $20.29. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:07 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,807 | $20.42 | $77,755.69 |
DisclosureSEC source: 0001725160-23-000031 · wf-form4_167641965116508.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,657 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.79 to $20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 1, 2023 19:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 132,646 | $0.00 Strike: $23.65 | $0.00 |
DisclosureSEC source: 0001725160-23-000020 · wf-form4_167529653658016.xml · derivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,646 Underlying: Common Stock · 132,646 shares Expires 2033-01-31 F3 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 1, 2023 19:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 91,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000020 · wf-form4_167529653658016.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 875,464 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| November 09, 2022 Filed Feb 1, 2023 19:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000020 · wf-form4_167529653658016.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,110 Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 18:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $22.21 | $0.00 |
DisclosureSEC source: 0001725160-22-000179 · wf-form4_166483672538571.xml · derivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-10-02 F3 · derivative.exercise_date: The options were granted by the Issuer under the 2020 Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 18:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000179 · wf-form4_166483672538571.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,110 F1 · shares: Represents restricted stock units ("RSUs") granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2020 Incentive Award Plan, as amended (the "2020 Plan"). The RSUs will vest over two years: 1/3 of the RSUs will vest on the first anniversary of the date of grant, and the remaining 2/3 of the RSUs will vest on the second anniversary of the date of grant. Read SEC document |
| August 10, 2022 Filed Aug 12, 2022 16:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001725160-22-000159 · wf-form4_166033599038928.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 95,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires October 31, 2022. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 20, 2022 Filed Jul 20, 2022 20:28 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,000 | $30.00 | $150,000.00 |
DisclosureSEC source: 0001725160-22-000135 · wf-form4_165836329544214.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 14, 2022 Filed Jul 14, 2022 18:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,290 | $30.01 | $98,721.06 |
DisclosureSEC source: 0001725160-22-000133 · wf-form4_165783821595135.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 105,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.03. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 13, 2022 Filed Jul 14, 2022 18:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,710 | $30.02 | $51,341.04 |
DisclosureSEC source: 0001725160-22-000133 · wf-form4_165783821595135.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 108,290 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.06. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 16:19 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 25,000 | $30.07 | $751,652.50 |
DisclosureSEC source: 0001725160-22-000131 · wf-form4_165713875110626.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 110,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.46. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $33.16 | $3,316.00 |
DisclosureSEC source: 0001725160-22-000078 · wf-form4_164988682369885.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 135,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 300 | $32.40 | $9,720.00 |
DisclosureSEC source: 0001725160-22-000078 · wf-form4_164988682369885.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 135,100 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $32.00 to $32.84. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| April 11, 2022 Filed Apr 13, 2022 17:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,600 | $30.37 | $139,708.90 |
DisclosureSEC source: 0001725160-22-000078 · wf-form4_164988682369885.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 135,400 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.02 to $30.61. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 21, 2022 Filed Mar 21, 2022 19:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,444 | $49.50 | $219,990.44 |
DisclosureSEC source: 0001725160-22-000063 · wf-form4_164790693534037.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 140,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.09 to $49.92. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 21, 2022 Filed Mar 21, 2022 19:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,556 | $48.72 | $270,679.43 |
DisclosureSEC source: 0001725160-22-000063 · wf-form4_164790693534037.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 144,444 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.08 to $49.07. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 10, 2022 Filed Mar 10, 2022 17:41 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,699 | $47.99 | $81,538.07 |
DisclosureSEC source: 0001725160-22-000059 · wf-form4_164695207751242.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 150,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.74 to $48.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 10, 2022 Filed Mar 10, 2022 17:41 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,301 | $47.18 | $202,900.97 |
DisclosureSEC source: 0001725160-22-000059 · wf-form4_164695207751242.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 151,699 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.72 to $47.63. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 10, 2022 Filed Mar 10, 2022 17:41 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,000 | $46.23 | $184,935.20 |
DisclosureSEC source: 0001725160-22-000059 · wf-form4_164695207751242.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 156,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.69 to $46.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 20:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 406 | $50.39 | $20,457.20 |
DisclosureSEC source: 0001725160-22-000048 · wf-form4_164566512930003.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 160,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.33 to $50.52. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 20:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,451 | $49.92 | $122,350.73 |
DisclosureSEC source: 0001725160-22-000048 · wf-form4_164566512930003.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 160,406 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.33 to $50.29. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 20:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,343 | $48.95 | $310,462.58 |
DisclosureSEC source: 0001725160-22-000048 · wf-form4_164566512930003.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 162,857 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.33 to $49.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 20:12 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 800 | $47.08 | $37,662.80 |
DisclosureSEC source: 0001725160-22-000048 · wf-form4_164566512930003.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 169,200 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.69 to $47.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 14, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,863 | $50.29 | $143,970.25 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 8 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,110 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F11 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.97 to $50.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 203 | $50.75 | $10,301.68 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 7 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,973 F8 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F10 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.58 to $50.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,622 | $50.16 | $81,366.33 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 6 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 767,176 F8 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F9 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.58 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 52,745 | $0.00 Strike: $52.61 | $0.00 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · derivative · entry 10 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,745 Underlying: Common Stock · 52,745 shares Expires 2032-02-09 F12 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,239 | $54.96 | $68,096.93 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 170,000 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.72 to $55.41. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,321 | $54.20 | $180,002.52 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 171,239 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.71 to $54.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,074 | $53.19 | $163,501.76 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 174,560 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.69 to $53.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,366 | $52.15 | $123,393.76 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 177,634 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.68 to $52.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 22,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000036 · wf-form4_164489104767793.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 768,798 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 710 | $61.29 | $43,518.10 |
DisclosureSEC source: 0001725160-22-000014 · wf-form4_164272407350854.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 180,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $61.12 to $61.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,537 | $60.20 | $393,505.17 |
DisclosureSEC source: 0001725160-22-000014 · wf-form4_164272407350854.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 180,710 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $59.77 to $60.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 20, 2022 Filed Jan 20, 2022 19:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,753 | $59.17 | $162,888.68 |
DisclosureSEC source: 0001725160-22-000014 · wf-form4_164272407350854.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 187,247 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $58.66 to $59.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 18:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,212 | $70.02 | $154,893.09 |
DisclosureSEC source: 0001725160-22-000009 · wf-form4_164194531939639.xml · nonDerivative · entry 5 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 190,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $69.65 to $70.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 18:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,835 | $69.03 | $126,663.08 |
DisclosureSEC source: 0001725160-22-000009 · wf-form4_164194531939639.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 192,212 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $68.65 to $69.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 18:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,807 | $68.05 | $191,012.70 |
DisclosureSEC source: 0001725160-22-000009 · wf-form4_164194531939639.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 194,047 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.63 to $68.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 10, 2022 Filed Jan 11, 2022 18:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,146 | $67.24 | $211,528.23 |
DisclosureSEC source: 0001725160-22-000009 · wf-form4_164194531939639.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 196,854 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.62 to $67.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 30, 2021 Filed Jan 11, 2022 18:55 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000009 · wf-form4_164194531939639.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,317 Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 18:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,071 | $80.76 | $167,253.13 |
DisclosureSEC source: 0001725160-21-000244 · wf-form4_164012865800357.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 200,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.25 to $81.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 18:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,889 | $79.78 | $310,266.36 |
DisclosureSEC source: 0001725160-21-000244 · wf-form4_164012865800357.xml · nonDerivative · entry 3 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 202,071 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.23 to $80.22. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 18:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,879 | $78.52 | $147,541.52 |
DisclosureSEC source: 0001725160-21-000244 · wf-form4_164012865800357.xml · nonDerivative · entry 2 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 205,960 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.10 to $79.04. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 18:17 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,161 | $77.45 | $167,369.67 |
DisclosureSEC source: 0001725160-21-000244 · wf-form4_164012865800357.xml · nonDerivative · entry 1 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 207,839 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.99 to $77.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 18:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 400 | $73.75 | $29,500.00 |
DisclosureSEC source: 0001725160-21-000238 · wf-form4_163943697239815.xml · nonDerivative · entry 4 Bunker Kevin D. · CIK 0001807484 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 210,000 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $73.38 to $74.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.